sabato, 5 dicembre 2020
9 Aprile 2018

FDA Expands Rucaparib Approval to Include Maintenance Treatment of Recurrent Ovarian Cancer

April 6, 2018 – Today, the U.S. Food and Drug Administration (FDA) approved rucaparib tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to platinum-based chemotherapy. The FDA granted regular approval for rucaparib in this second, broader, and earlier-line indication on a Priority Review timeline based on positive data from the phase … (leggi tutto)